甲巯丙脯酸加阿魏酸钠对原发性高血压患者降压效果及尿中血栓素B<sub>2</sub>排泄影响

本实验将原发性高血压患者44例随机分为两组,观察单独口服甲巯丙脯酸（CAP）和 CAP 与阿魏酸钠（SF）联合服用后平均动脉压（MAP）、尿中 TXB₂浓度及血中血管紧张素转化酶（ACE）活性的变化。结果表明,CAP 使原发性高血压患者血中 ACE 活性减低,有显著降压作用,但尿中 TXB₂排泄增加;SF 无降压作用,与 CAP 联合应用可使原发性高血压患者服用 CAP 后尿中 TXB₂ 排泄增加受到抑制,降压作用得到加强。

英文摘要:

In the present study, the influence of sodium ferulate（SF） on hypotensive effect and urinary excretion of TXB₂ after captopril （CAP） was observed in 44 patients with essential hypertension.A single oral dose of CAP（50 mg）decreased mean arterial pressure （MAP） from 16.25±0.85 to 13.65± 1.14 kPa, n=28,（P<0.01）,and increased urinary TXB₂ excretion significantly from 119.12±57.12 to 183.32±78.61 pg/min,n=16,（P<0.05）.The administration of SF 300 mg/d for one day did not affect the MAP.CAP in combination with SF induced a decrease both in MAP from 16.33±1.14 to 13.83± 1.77kPa, n=16,（P<0.01） and urinary TXB₂ excretion from 155.89±69.64 to 133.43±60.01 pg/min, n=16,（P>0.05）though the latter was not so significant.Compared with the administration of CAP alone,the combination of CAP and SF induced stronger hypotensive effect （P<0.05） and the increased urinary TXB₂ excretion could be inhibited by SF.but the inhibition to angiotensin converting enzyme was the same.These results suggested that the increased urinary TXB₂ excretion by CAP can be inhibited and the hypotensive effect of CAP is potentiated by SF in essential hypertensive patients.

关闭